Sjögren's syndrome
Enable an AI agent to recognise evidence relevant to Sjögren's syndrome, describe its glandular and systemic state, and identify appropriate assessment and care options for clinician review.
Research draft, second pass
A second pass drafted this model: the structure a model of this thing needs, and what is known about it in the world. The line under this one says how the second half was obtained - researched against sources, or recalled without web access, in which case nothing here was read anywhere and every claim is a lead to verify. Unreviewed either way.
recalled by Codex without web access - no source was read
Researched by: Codex
Purpose and description
Enable an AI agent to recognise evidence relevant to Sjögren's syndrome, describe its glandular and systemic state, and identify appropriate assessment and care options for clinician review.
Sjögren's syndrome is a chronic systemic autoimmune disease characterised by lymphocytic inflammation and dysfunction of exocrine glands, especially the salivary and lacrimal glands, commonly causing dry mouth and dry eyes and sometimes affecting other organs.
It can be Organise diagnostic evidence and identify missing or conflicting investigations for clinician review.; Assess a named classification framework only when its eligibility, exclusions and required inputs are available.; Compare glandular function, systemic findings and patient-reported burden across dated assessments.; Identify findings requiring review under a sourced, current escalation pathway.; Connect each proposed intervention to a specific manifestation, treatment target and monitoring requirement.; Produce a traceable disease-state summary that preserves uncertainty and links to original evidence..
Distinguishing features
Test whether dryness has objective glandular evidence and an evaluated cause; dry eyes or dry mouth alone should not establish the disease identity.
Separate anti-SSA/Ro results, other antibody findings, gland histology and functional tests instead of treating all positive investigations as interchangeable.
Distinguish a clinician's diagnostic conclusion from fulfilment of a named, dated classification framework.
Assess systemic features even when dryness is limited, absent or poorly documented.
Represent Sjögren's syndrome alongside another autoimmune disease without automatically attributing every manifestation to either condition.
Scope
+ Evidence supporting or challenging Sjögren's syndrome, including diagnostic reasoning and versioned classification criteria
+ Lacrimal and salivary dysfunction, associated symptoms and glandular consequences
+ Systemic manifestations, symptom burden, disease activity and accumulated damage
+ Disease relationships, alternative explanations and overlapping autoimmune conditions
+ Longitudinal monitoring, treatment targets, response and escalation considerations
- The patient's complete demographic and medical record
- Appointment, referral, admission and billing workflows
- Standalone models of rheumatoid arthritis, systemic lupus erythematosus and other associated conditions
- General pharmacology and prescribing rules for individual medicines
- Laboratory instrument specifications and assay manufacturing
- Independent models of dental disease, ocular disease and lymphoma
Characteristics
- Diagnostic assertion
- Suspected, clinician-diagnosed, uncertain, reconsidered; assessor and date Preserves the distinction between the disease and a revisable conclusion about its presence.
- Classification assessment
- Framework, issuer, version, eligibility, exclusions, component results and met/not met/not assessable outcome Makes criteria-based conclusions reproducible without equating classification with diagnosis.
- Autoantibody evidence
- Antibody specificity, assay, result, laboratory units, reference interval and collection date Prevents loss of distinctions between anti-SSA/Ro, anti-SSB/La and other serological evidence.
- Lacrimal function and ocular surface findings
- Schirmer result in mm over the recorded duration; ocular staining score with named scale; eye and date Separates tear production from ocular surface injury and subjective discomfort.
- Salivary function
- Flow in mL/min, stimulated or unstimulated protocol, collection conditions and date Supports interpretation of gland function and comparison over time.
- Salivary gland histopathology
- Biopsy site, tissue adequacy, histological interpretation and focus score per 4 mm² when reported Keeps the numerical result attached to the specimen quality and pathological interpretation needed to assess it.
- Systemic involvement
- Organ domain, manifestation, severity, attribution confidence and assessment date Supports decisions beyond management of dryness.
- Patient-reported symptom burden
- Dryness, fatigue and pain scores with instrument, version, range and date Captures burden that may differ from measured systemic disease activity.
- Activity and damage
- Active, stable, improving, worsening, residual damage or uncertain; supporting observations Distinguishes potentially treatable activity from persistent consequences.
- Associated autoimmune disease
- Linked condition, diagnostic evidence and relationship terminology used by the source Preserves overlap and attribution uncertainty without creating a duplicate disease model.
- Terminology mapping
- Verified ICD-10, ICD-11 or SNOMED CT concept, edition, jurisdiction and mapping scope Prevents unversioned codes or approximate mappings from silently changing the represented concept.
Also called
Where this came from
wikidata · CC0 1.0
Drafted structure
Bundle to layer to finding to question, as the second pass will find it: 6 bundles · 11 layers · 19 findings · 33 questions.
Disease identity and evidence Establish what supports Sjögren's syndrome and how the diagnostic conclusion was reached.
Dryness, serological findings and classification outcomes must not collapse into an unsupported disease label.
Diagnosis and classification
Separate clinical judgment from formal classification and terminology mappings.
Basis of disease identification
Record the diagnostic assertion, its evidence and any separately assessed classification outcome.
- Who asserted Sjögren's syndrome, when, and with what supporting evidence and degree of certainty? provenance
- Which classification framework, issuing body and version were used, and were eligibility and exclusion conditions assessed? definition
- Which verified terminology concepts map to this disease, and which instead describe a manifestation or encounter? boundary
Serology, histology and alternatives
Interpret autoimmune and tissue evidence alongside competing explanations.
Evidence concordance
Preserve agreement, disagreement and limitations across antibody testing, biopsy and differential assessment.
- What do anti-SSA/Ro testing and any salivary gland biopsy show, including assay details, tissue adequacy and specialist interpretation? measurement
- Which alternative causes of sicca or gland enlargement were assessed, including medication effects and relevant mimicking conditions? boundary
- What further review is justified when clinical findings, serology and histology disagree? action
Lacrimal and salivary state Describe tear and saliva function, symptoms and local consequences.
Sjögren's assessment needs separate accounts of perceived dryness, measured secretion and tissue injury.
Ocular function and injury
Connect ocular symptoms with tear testing and ocular surface examination.
Ocular sicca profile
Record each eye's symptoms, functional results and surface findings without assuming that they track together.
- What are the dated Schirmer and ocular staining results, including protocol, scoring system and eye tested? measurement
- How do discomfort, visual interference and examination findings compare, and what other ocular causes remain plausible? boundary
Oral function and gland state
Assess salivary output, gland changes and consequences for oral function.
Salivary dysfunction profile
Link measured secretion and gland findings with eating, swallowing, speaking and oral health.
- What salivary flow was measured, under which stimulation and collection conditions, and with which potential confounders? measurement
- What gland swelling, oral discomfort, dental deterioration or swallowing difficulty is documented, and how confidently is it attributed to Sjögren's syndrome? boundary
Systemic involvement and complications Represent manifestations beyond the exocrine glands and findings needing additional investigation.
A dryness-only model cannot describe systemic disease or support appropriate escalation.
Organ manifestations and attribution
Assess involvement across relevant organs while retaining competing explanations.
Systemic manifestation assessment
Capture suspected or established pulmonary, renal, neurological, cutaneous, articular and haematological involvement.
- Which systemic manifestations are present, what objective evidence supports them, and how severe are they? measurement
- Could each manifestation reflect an associated autoimmune condition, infection, treatment effect or unrelated disease? boundary
Lymphoproliferative and other alerts
Track unexplained changes requiring evaluation without treating them as confirmed complications.
Complication review triggers
Connect concerning glandular, lymphatic or systemic changes to a sourced assessment pathway.
- Are persistent or asymmetric gland enlargement, lymphadenopathy, unexplained constitutional symptoms or relevant laboratory changes documented? measurement
- Which current clinical pathway determines the urgency and type of assessment, and has that assessment occurred? action
Burden, activity and course Track the relationship between symptoms, systemic activity and accumulated consequences over time.
Patient burden, inflammatory activity and irreversible damage support different judgments and care targets.
Symptoms and daily function
Represent dryness, fatigue, pain and their effects on daily life.
Patient-experienced burden
Record symptom scores and practical limitations together with potential contributors.
- How severe are dryness, fatigue and pain using a named instrument such as ESSPRI, with its version and assessment date? measurement
- Which daily activities are affected, and which concurrent conditions or exposures may contribute to the reported burden? boundary
Activity, damage and trajectory
Compare dated assessments without imposing an unsupported universal stage sequence.
Longitudinal disease state
Separate current systemic activity, persistent dysfunction and uncertain change.
- What systemic activity is recorded using a named instrument such as ESSDAI, including version, domain evidence and date? measurement
- Which changes represent active disease, established damage, treatment effects or unresolved attribution? boundary
- Are apparent trends interpretable given changes in tests, assessors, treatment and observation intervals? provenance
Manifestation-directed care Relate potential care actions to disease manifestations, patient priorities and observed outcomes.
Local dryness care and management of systemic involvement require distinct indications and measures of benefit.
Local care and prevention
Connect ocular and oral care to functional deficits and preventable consequences.
Glandular care targets
Record clinician-reviewed options, intended benefits and follow-up for ocular and oral manifestations.
- Which ocular or oral problem is each intervention intended to address, and what current guidance supports its use? action
- What symptom, examination or oral-health outcome will indicate benefit, intolerance or need for specialist reassessment? measurement
Systemic care and response
Link systemic treatment decisions to attributed manifestations and monitored outcomes.
Systemic treatment justification
Preserve the indication, supporting guidance, constraints and response for clinician-directed systemic care.
- Which attributed manifestation and severity justify consideration of systemic treatment under the applicable guideline? action
- What disease outcomes and treatment safety observations determine continuation, adjustment or escalation? measurement
- Which associated conditions, current medicines or patient priorities materially constrain the proposed option? boundary
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- This is a recall-based description; no sources were consulted. Verify exact criteria wording, exclusions and applicable coding revisions before publication.
- The cause is incompletely established, the course is heterogeneous, and no single universal staging sequence applies; disease, diagnostic classification and an episode of care are distinct.
- The disease predominantly affects women and is often recognised in middle adulthood, but occurs across ages and sexes; population-specific prevalence and current terminology should be checked.
- Which of these check these first hold for the sense of Sjögren's syndrome this model covers, and on what evidence? provenance
Kinds and varieties
Recalled without web access and unsourced; every item is a lead to verify.
- Primary Sjögren's syndrome
- Sjögren's syndrome associated with another systemic autoimmune disease, traditionally called secondary Sjögren's syndrome
- Which of these kinds and varieties hold for the sense of Sjögren's syndrome this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- WHO ICD-10 - M35.0 - Sicca syndrome [Sjögren]; national clinical modifications may add subcodes, so the jurisdiction and revision must accompany the code.
- Which of these identifiers and schemes hold for the sense of Sjögren's syndrome this model covers, and on what evidence? provenance
Standards and regulation
Recalled without web access and unsourced; every item is a lead to verify.
- 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a weighted score of at least 4 in eligible individuals after specified exclusions; classification criteria support research consistency and are not a substitute for clinical diagnosis.
- EULAR recommendations for management of Sjögren's syndrome with topical and systemic therapies.
- Which of these standards and regulation hold for the sense of Sjögren's syndrome this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Clinical evaluation of persistent eye and mouth dryness, gland swelling, fatigue or systemic manifestations.
- Selection of sufficiently comparable participants for research using explicitly versioned classification criteria.
- Assessment of systemic disease activity and patient-reported symptom burden.
- Coordination of rheumatology, ophthalmology and dental care.
- Longitudinal monitoring for organ involvement and lymphoma.
- Which of these real-world use hold for the sense of Sjögren's syndrome this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Schirmer test tear production - 2016 classification threshold: 5 or less in at least one eye over 5 minutes; this is a criterion threshold, not a typical patient range. - mm of strip wetting
- Unstimulated whole salivary flow - 2016 classification threshold: 0.1 or less; this is a criterion threshold, not a typical patient range. - mL/min
- Labial salivary gland biopsy focus score - 2016 classification threshold: at least 1 in the presence of focal lymphocytic sialadenitis; a focus contains at least 50 mononuclear cells. - foci per 4 mm² of glandular tissue
- EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) - 0-10 instrument scale, averaging patient ratings of dryness, fatigue and pain. - score
- Which of these typical measurements hold for the sense of Sjögren's syndrome this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Mistaking medication-related or other non-autoimmune dryness for Sjögren's syndrome.
- Excluding the disease solely because anti-SSA/Ro antibodies are absent, or diagnosing it solely from a positive antibody result.
- Dental caries, oral candidiasis and ocular surface injury associated with impaired secretions.
- Extraglandular disease, including interstitial lung disease, peripheral neuropathy and renal tubular involvement.
- Increased risk of B-cell non-Hodgkin lymphoma, particularly mucosa-associated lymphoid tissue lymphoma.
- Which of these failure modes and hazards hold for the sense of Sjögren's syndrome this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Prevalence estimates depend on population, ascertainment method and classification criteria; estimates from different regions are not automatically comparable.
- Administrative coding varies between WHO ICD-10 and national clinical modifications.
- Which of these regional variation hold for the sense of Sjögren's syndrome this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Sicca symptoms - Dry eyes and dry mouth are symptoms with multiple causes; Sjögren's syndrome requires evidence supporting an autoimmune disease.
- IgG4-related disease - It can cause lacrimal and salivary gland enlargement, but its characteristic tissue pathology and clinicopathological findings distinguish it; it is an exclusion in the 2016 classification criteria.
- Systemic lupus erythematosus - It has a distinct clinical and immunological pattern; anti-SSA/Ro antibodies can occur in both, and the diseases may coexist.
- Rheumatoid arthritis - Persistent inflammatory synovitis defines its principal clinical pattern; associated Sjögren's syndrome describes an additional autoimmune disease rather than the arthritis itself.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of Sjögren's syndrome this model covers, and on what evidence? provenance
What the second pass must settle
- Which current diagnostic guidance and classification frameworks should be represented, and how do their applicability and evidence differ for adults, children and seronegative presentations?
- What exact ICD-10, ICD-11 and SNOMED CT concepts match this registry entry in the intended editions and jurisdictions, including terminology changes between syndrome and disease?
- How should salivary gland ultrasound contribute to diagnostic reasoning and follow-up under the selected guidance, and which acquisition and scoring protocols are supported?
- Which complication predictors and escalation pathways have sufficient evidence for the intended population, particularly for lymphoproliferative disease?
- What prevalence estimates, affected-population patterns and longitudinal outcomes are supported by sources that specify geography, ascertainment method, criteria and study year?